Short Interest in Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Declines By 85.4%

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) saw a significant decline in short interest in August. As of August 31st, there was short interest totaling 1,269 shares, a decline of 85.4% from the August 15th total of 8,695 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 24,351 shares, the days-to-cover ratio is currently 0.1 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Millennium Management LLC purchased a new stake in Oaktree Acquisition Corp. III Life Sciences during the 1st quarter worth approximately $4,848,000. Goldman Sachs Group Inc. purchased a new position in shares of Oaktree Acquisition Corp. III Life Sciences during the 1st quarter valued at approximately $5,417,000. JPMorgan Chase & Co. acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the second quarter worth approximately $2,094,000. Whitebox Advisors LLC acquired a new stake in shares of Oaktree Acquisition Corp. III Life Sciences during the second quarter worth approximately $2,612,000. Finally, Lighthouse Investment Partners LLC increased its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 88.9% in the second quarter. Lighthouse Investment Partners LLC now owns 850,000 shares of the company’s stock worth $8,882,000 after buying an additional 400,000 shares during the last quarter.

Oaktree Acquisition Corp. III Life Sciences Price Performance

Shares of OACC stock traded up $0.01 on Friday, hitting $10.78. The stock had a trading volume of 850 shares, compared to its average volume of 36,225. The stock’s 50 day moving average is $10.75 and its 200-day moving average is $10.70. Oaktree Acquisition Corp. III Life Sciences has a 52-week low of $10.44 and a 52-week high of $10.88.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last released its quarterly earnings results on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Oaktree Acquisition Corp. III Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, August 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity.